Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)N. Costedoat‐Chalumeau, Alain Dupuy, Du Le Thi Huong Boutin et al.|Annals of the Rheumatic Diseases|2012Cited by 207
Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndromeAurélien Delluc, P. Cacoub, Nicolas Limal et al.|Annals of the Rheumatic Diseases|2008Cited by 69
Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case–control study with hydroxychloroquine blood-level analysisTiphaine Lenfant, Olivier Fain, Gaëlle Leroux et al.|Lara D. Veeken|2020Cited by 51
Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherenceBenoı̂t Blanchet, Aurélien Delluc, M. Jallouli et al.|Arthritis Research & Therapy|2020Cited by 30
Efficacy of chimeric antigen receptor engineered natural killer cells in the treatment of hematologic malignancies: a systematic review and meta-analysis of preclinical studiesDonald Bastin, Alissa Visram, Marisa K. Kilgour et al.|Cytotherapy|2024Cited by 6